David G. Trist

2.0k total citations
62 papers, 1.5k citations indexed

About

David G. Trist is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, David G. Trist has authored 62 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Cellular and Molecular Neuroscience, 37 papers in Molecular Biology and 6 papers in Pharmacology. Recurrent topics in David G. Trist's work include Receptor Mechanisms and Signaling (25 papers), Neuropeptides and Animal Physiology (18 papers) and Neuroscience and Neuropharmacology Research (18 papers). David G. Trist is often cited by papers focused on Receptor Mechanisms and Signaling (25 papers), Neuropeptides and Animal Physiology (18 papers) and Neuroscience and Neuropharmacology Research (18 papers). David G. Trist collaborates with scholars based in Italy, United Kingdom and United States. David G. Trist's co-authors include Emiliangelo Ratti, Claudio Pietra, Stéfano Palea, Walter Artibani, Edoardo Ostardo, M. Corsi, Francesco Crespi, G. Gaviraghi, Mauro Corsi and Manolo Mugnaini and has published in prestigious journals such as Annals of the New York Academy of Sciences, Journal of Medicinal Chemistry and The Journal of Urology.

In The Last Decade

David G. Trist

62 papers receiving 1.4k citations

Peers

Countries citing papers authored by David G. Trist

Since Specialization

Citations

This map shows the geographic impact of David G. Trist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Trist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Trist more than expected).

Fields of papers citing papers by David G. Trist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Trist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Trist. The network helps show where David G. Trist may publish in the future.

Co-authorship network of co-authors of David G. Trist

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Trist. A scholar is included among the top collaborators of David G. Trist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Trist. David G. Trist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical pharmacology in neuroscience drug discovery: quo vadis? 2013 ·Current Opinion in Pharmacology ·David G. Trist, Adam F. Cohen, Alan Bye	3
2	Synthesis and structure–activity relationship of new 1,5-dialkyl-1,5-benzodiazepines as cholecystokinin-2 receptor antagonists 2011 ·Bioorganic & Medicinal Chemistry ·Karen Roberts, Antonella Ursini, Robert J. Barnaby, (unknown), Mauro Corsi, (unknown), Daniele Donati, Aldo Feriani, (unknown), Carla Marchioro, (unknown), Beatrice Oliosi, (unknown), Emiliangelo Ratti, Angelo Reggiani, Giovanna Tedesco, (unknown), David G. Trist, (unknown)	13
3	A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial 2010 ·European Neuropsychopharmacology ·Sanjay J. Mathew, Meena Vythilingam, James W. Murrough, Carlos A. Zarate, Adriana Feder, David A. Luckenbaugh, Becky Kinkead, Michael K. Parides, David G. Trist, Massimo Bani, P. Bettica, Emiliangelo Ratti, Dennis S. Charney	40
4	Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils 2009 ·Behavioural Pharmacology ·Scott A. Heldt, Michael T. Davis, Emiliangelo Ratti, Mauro Corsi, David G. Trist, Kerry J. Ressler	17
5	Differential Effects of the CRF-R1 Antagonist GSK876008 on Fear-Potentiated, Light- and CRF-Enhanced Startle Suggest Preferential Involvement in Sustained vs Phasic Threat Responses 2008 ·Neuropsychopharmacology ·David Walker, Yong Yang, Emiliangelo Ratti, Mauro Corsi, David G. Trist, Michael Davis	56
6	Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications 2000 ·Pharmaceutica Acta Helvetiae ·David G. Trist	54
7	NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson’s disease patients 1999 ·Neuropharmacology ·(unknown), Bernd Bunnemann, Ann E. Kingsbury, David G. Trist, Norman G. Bowery	21
8	N-terminal splice variants of the NMDAR1 glutamate receptor subunit: differential expression in human and monkey brain 1998 ·Neuroscience Letters ·(unknown), Bernd Bunnemann, David G. Trist, Norman G. Bowery	12
9	Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder 1998 ·British Journal of Pharmacology ·Stéfano Palea, (unknown), Claudio Pietra, David G. Trist, Walter Artibani, Oriana Romano, M. Corsi	64
10	Different Levels of Receptor Expression as a New Procedure to Estimate Agonist Affinity Constant 1997 ·Annals of the New York Academy of Sciences ·Corrado Corti, Paolo Cavanni, (unknown), Francesco Ferraguti, M. Corsi, David G. Trist	2
11	GV 150526A, 7-Cl-kynurenic acid and HA 966 antagonize the glycine enhancement of N-methyl-d-aspartate-induced [3H]noradrenaline and [3H]dopamine release 1997 ·European Journal of Pharmacology ·Tiziana Mennini, Laura Mancini, Angelo Reggiani, David G. Trist	6
12	Discrimination by benextramine between the NPY‐Y₁ receptor subtypes present in rabbit isolated vas deferens and saphenous vein 1995 ·British Journal of Pharmacology ·Stéfano Palea, M. Corsi, Joseph M. Rimland, David G. Trist	16
13	Failure of the putative neuropeptide Y antagonists, benextramine and PYX‐2, to inhibit Y₂receptors in rat isolated prostatic vas deferens 1995 ·British Journal of Pharmacology ·Stéfano Palea, M. Corsi, Joseph M. Rimland, David G. Trist, Emiliangelo Ratti	3
14	Evidence for the presence of both pre‐ and postjunctional P₂‐purinoceptor subtypes in human isolated urinary bladder 1995 ·British Journal of Pharmacology ·Stéfano Palea, Claudio Pietra, David G. Trist, Walter Artibani, (unknown), M. Corsi	21
15	Analysis of the CCK_B receptor antagonism of virginiamycin in guinea‐pig ileum longitudinal myenteric plexus 1993 ·British Journal of Pharmacology ·Martina Corsi, (unknown), (unknown), Claudio Pietra, G. Gaviraghi, David G. Trist	7
16	Further studies on the effects of selective neurokinin agonists upon the activation of micturition reflex in rats. Evidence for a dual NK-1 receptor mediated excitatory and inhibitory activity 1993 ·Neuropeptides ·Stéfano Palea, (unknown), G. Gaviraghi, R.M. Hagan, David G. Trist, Claudio Pietra	11
17	The Hemodynamic Effects of Lacidipine in Anesthetized Dogs 1991 ·Journal of Cardiovascular Pharmacology ·M. Quartaroli, (unknown), (unknown), (unknown), David G. Trist, G. Gaviraghi	6
18	The antagonism by BW A868C of PGD₂ and BW245C activation of human platelet adenylate cyclase 1989 ·British Journal of Pharmacology ·David G. Trist, (unknown), John R. Wood, Michael Kelly, Alan D. Robertson	42
19	Resultant action of cimetidine in a cardiac adenylate cyclase assay: its elucidation by concentration-ratios analysis. 1987 ·Journal of Pharmacology and Experimental Therapeutics ·David G. Trist, P. Leff, J. W. Black, V.P. Gerskowitch, Nigel P. Shankley	7
20	Mepacrine uptake by granulocytes [proceedings]. 1978 ·PubMed Central ·N G Read, David G. Trist	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact